XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

Summary

The purpose of this study is to determine how well the study drug XL092 is helping to treat a participant's cancer after 16 weeks of treatment. Researchers will also look at how safe the XL092 is and how well the XL092 is working. XL092 is an oral tablet that will be taken once a day. Participants will return to clinic for regular visits for checkups and tests.

Timeline

Start

2024-12-09

Primary completion

2026-12

Completion

2028-12

Drugs

Indications